Editorial
Intra-articular bupivacaine: potentially chondrotoxic?
The management of acute postoperative pain after orthopaedic surgery is a challenge for anaesthetists and surgeons. The administration of local anaesthetic drugs into the joint space, either by single injection or by continuous infusion, has become a well-recognized technique for postoperative analgesia, in particular after arthroscopic surgery. Bupivacaine is commonly used for intra-articular analgesia because of its long duration of action. Other local anaesthetics used for intra-articular analgesia include ropivacaine and lidocaine. Intra-articular use of these drugs has been widely regarded as safe, and adverse effects of local anaesthetic agents in the joint space have been reported only rarely. Peak plasma concentrations of bupivacaine are sufficiently low after intra-articular injection such that systemic toxicity is extremely unlikely. 1 However, overdose or inadvertent intravascular injection may result in central nervous system and cardiovascular toxicity. 2 3 Despite their widespread use, the effects of intra-articular local anaesthetic agents on joint structures have not been fully elucidated. Early evidence from animal experiments suggested that bupivacaine acutely inhibits the synthesis of articular cartilage. 4 A later study found that intra-articular bupivacaine 0.5% resulted in articular cartilage inflammation and synovial membrane changes in rabbit knee joints. 5 However, clinical reports of postoperative chondrolysis of the shoulder joint 6 -9 and ankle joint 10 after arthroscopic surgery, and the possible association with the use of intra-articular bupivacaine, have brought the safety of intra-articular local anaesthetics to the fore among orthopaedic surgeons.
Chondrolysis is a condition in which extensive loss of articular cartilage occurs over a relatively short period of time. After arthroscopic shoulder surgery, the consequences of postoperative glenohumeral chondrolysis are clearly devastating. The condition typically occurs in young athletes and effective treatment options are limited. The pain and reduced mobility associated with chondrolysis tend to progress to severe osteoarthritis, which may eventually require joint arthroplasty. The largest series of cases of post-arthroscopic glenohumeral chondrolysis (PAGCL) described 12 cases. 7 The authors state that the common factor in all cases was the postoperative administration of an intra-articular infusion of bupivacaine with epinephrine. In total, 27 cases of PAGCL have been reported, with 25 of these cases having received postoperative continuous intra-articular analgesia with bupivacaine. 7 -9 Recently, a number of experimental studies have suggested that local anaesthetics may damage articular cartilage. It has been shown that bupivacaine 0.5% is toxic to both bovine articular chondrocyte cultures and bovine articular osteochondral tissue. 11 The effect of bupivacaine on human cartilage has also been analysed. The effects of bupivacaine 0.5%, bupivacaine 0.25%, bupivacaine 0.125%, and saline 0.9% on bovine and human articular chondrocyte cultures were compared. 12 Both bupivacaine 0.5% and bupivacaine 0.25% displayed dose-dependent and time-dependent chondrotoxicity. The toxicity of bupivacaine 0.5% was more marked than bupivacaine 0.25% at all time points. The toxicity of both drugs increased as the duration of exposure increased (from 15 to 60 min) and as the time after exposure increased (from 1 h to 1 week). The effect of bupivacaine 0.125% on bovine and human articular chondrocytes was no different from 0.9% saline. The effects of different concentrations of bupivacaine on bovine articular osteochondral tissue were also compared. Again, both bupivacaine 0.5% and bupivacaine 0.25% demonstrated dose-dependent chondrotoxicity. However, the effect of bupivacaine 0.125% was not different from 0.9% saline.
Although less profound than the effects of bupivacaine, lidocaine 1% and lidocaine 2% also exhibit dosedependent and time-dependent toxic effects on bovine articular chondrocytes. 13 Ropivacaine is the third local anaesthetic to be associated with chrondrotoxicity.
14 The effects of bupivacaine 0.5% and ropivacaine 0.5% on both human articular chondrocyte cultures and human articular cartilage explants were compared. Although ropivacaine 0.5% was toxic to chondrocyte cultures, it was significantly less toxic than bupivacaine 0.5%. On exposure of cartilage explants to both local anaesthetic agents, the effect of ropivacaine 0.5% was no different from that of 0.9% saline, whereas bupivacaine 0.5% did demonstrate chondrotoxicity.
Other studies have tested the effects of continuous administration of local anaesthetic agents on intra-articular structures. In an experimental animal model, the 48 h intra-articular infusion of bupivacaine 0.25%, both with and without epinephrine, resulted in significant histopathological and metabolic changes in rabbit shoulder joints after 1 week. 15 However, using the same model, no significant histopathological changes were found 3 months after the 48 h intra-articular infusion of bupivacaine, both with and without epinephrine. 16 Metabolic effects consistent with increased articular cartilage synthesis, which may represent a reparative process, could, however, be demonstrated.
Another study investigated the in vitro effects of the 72 h administration of lidocaine 1%, bupivacaine 0.25%, and bupivacaine 0.5%, each with and without epinephrine, on human articular chondrocyte cultures. 17 All of the local anaesthetic solutions containing epinephrine resulted in significant chondrocyte necrosis at 24, 48, and 72 h. None of the local anaesthetic solutions which did not contain epinephrine caused chondrocyte necrosis at 24 h. However, significant chondrocyte necrosis developed after 48 h exposure to lidocaine 1% and after 72 h exposure to bupivacaine 0.5%.
The pathogenesis and aetiology of postoperative chondrolysis are unclear and the clinical entity remains poorly understood. The condition is rare and only a small number of case series have been published. However, information about PAGCL is widely available in the public domain and a number of lawsuits have been filed in the USA against infusion device manufacturers for personal injury caused by the condition. In addition to local anaesthetics, other aetiological factors have been implicated in postoperative chondrolysis and the cause may be multifactorial. These factors include an exaggerated inflammatory response to bioabsorbable implants, 18 therapeutic use of thermal energy devices, 19 inadvertant intra-articular injection of methylmethacrylate bone cement, 20 accidental joint irrigation with chlorhexidine, 21 or pre-existing low-grade joint infection. 8 A further consideration in the aetiology of postoperative chondrolysis is the effect of intra-articular epinephrine. Local anaesthetic solutions administered into the joint space may or may not contain epinephrine. Evidence relating to the role of epinephrine in contributing to cartilage damage has yet to be elucidated. Similarly, the effect of preservative agents in local anaesthetic solutions on intra-articular surfaces needs to be defined.
Single intra-articular local anaesthetic injections are well established in clinical practice. In contrast, the technique of continuous intra-articular delivery of local anaesthetic using a 'pain pump' is a relatively new innovation that has become increasingly popular, particularly in North American practice. It is notable that adverse clinical effects appear to occur only after continuous intra-articular infusions of bupivacaine, but not after single injections.
A number of comments can be made with regard to the experimental studies when viewed in the light of the recent clinical reports and the emerging medico-legal ramifications. First, it should be noted that hyaline cartilage, which covers the articular surface of synovial joints, is an avascular tissue which is dependent on synovial fluid for its metabolic supply; intra-articular administration of any fluid may dilute, displace, or alter the composition of synovial fluid, thus compromising the nutritional supply to articular cartilage. Secondly, the potential chondrotoxic effects of intra-articular local anaesthetics in clinical practice may be quite different from the experimental effects. Clinical effects may be modified by multiple factors including the following: the protective effect of intact articular cartilage as opposed to chondrocytes or osteochondral tissue used in experimental studies, the pre-existing pathological state of the articular cartilage, local absorption of the drug into joint structures, dilution of the drug by synovial fluid and arthroscopic lavage fluid, and ongoing joint reparative processes.
In conclusion, the demonstration of dose-dependent and time-dependent human chondrotoxicity of local anaesthetics, particularly bupivacaine, suggests that prolonged, continuous intra-articular administration of higher concentrations of bupivacaine may result in adverse clinical effects, whereas a single injection of low-concentration bupivacaine appears to be safe. Further investigation should aim to elucidate the aetiology of PAGCL and provide clarity into the role, if any, of intra-articular local anaesthetics. Much larger case -control studies will be required to determine the possible causative factors involved in the condition. The putative benefits of continuous intra-articular local anaesthetic infusions, including better pain relief, improved mobilization, and shorter hospital stay, are worthy aims. However, novel techniques must not compromise patient safety. We should be prepared to modify our approach to drug usage in the light of new knowledge of adverse effects.
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